Optimization Bispecific Antibodies Downstream Processing: Seeking Homodimer Removal

Bispecific antibodies (BsAbs) have gained significant attention in the field of therapeutics due to their ability to simultaneously target multiple disease-related antigens. However, the production and purification of BsAbs present unique challenges compared to traditional monoclonal antibodies. One critical downstream processing step in the production of bispecific antibodies is the removal of unwanted homodimers, which can affect the efficacy and safety of the final product. In Polpharma Biologics, optimized downstream processing strategies were developed for BsAbs biosimilars with a specific emphasis on homodimer removal.